Neurotune launches sarcopenia test to speed up own drug development
This article was originally published in Clinica
Biotech firm Neurotune has launched for research use a diagnostic for sarcopenia, a muscle loss disorder. It believes the test will help accelerate the development of its own pipeline of drugs for the disease. The test, which the firm claims is the first available for sarcopenia, could help to stratify patients, thereby allowing more targeted clinical trials. It could eventually be marketed as a companion diagnostic for use alongside these drugs, if approved.